What should I do if I become drug-resistant after taking Tivozanib?

Tivozanib's biggest advantage is tolerability. It is a very clean drug, has little effect on VEGF, and is very well tolerated in terms of side effects and the need to interrupt or reduce doses. The recommended oral dose reaches peak plasma concentration approximately 2 to 24 hours later. The half-life is approximately four days. Drug accumulation at steady state is 6-7 times higher compared to single-dose exposure. There were no time-dependent changes in pharmacokinetics, whereas acute and chronic administration showed similar clearance.

Renal cell carcinoma is a chemoresistant tumor due to its unique genetically defined resistance to chemotherapy and radiotherapy. Oncolytic peptide nanomachines overcome drug resistance in kidney cancer by dissolving cell membranes. Results from the TIVO-1 and TIVO-3 trials suggest that tivozanib has a favorable safety profile in patients with advanced kidney cancer, resulting in relatively low rates of dose reductions, treatment interruptions, or discontinuations. A recent Ib/II clinical study showed that the tivozanib/nivolumab combination had a tolerable safety profile and good efficacy. The combination controlled disease in 96% of patients and showed a median PFS of 18.9 months, which was similar for treatment-naive and previously treated patients. Ongoing studies, such as the phase 3 TiNivo-2 trial, are examining tivozanib in combination with immune checkpoint inhibitors.

The original drug Tivozanib has not yet been marketed in the country, so it has not been included in medical insurance. The European version of tivozanib Original drug, specifications1340mcg*21 pills sold overseas may cost around 30,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively expensive. There is currently no generic version of tivozanib available on the market. For more drug information and specific prices, please consult a medical consultant.